Table 6 |
||
|
Most frequently reported adverse events that occurred at a frequency of >10% in either group of patients enrolled in comparator studies [7,8,52] |
||
|
Adverse event preferred term |
AL n(%) n = 314 |
MAS n(%) n = 105 |
|
|
||
|
Pyrexia |
183 (58.3) |
63 (60.0) |
|
Headache |
166 (52.9) |
46 (43.8) |
|
Dizziness |
123 (39.2) |
37 (35.2) |
|
Anorexia |
108 (34.4) |
37 (35.2) |
|
Asthenia |
108 (34.4) |
33 (31.4) |
|
Arthralgia |
99 (31.5) |
31 (29.5) |
|
Nausea |
82 (26.1) |
34 (32.4) |
|
Myalgia |
74 (23.6) |
19 (18.1) |
|
Sleep disorder |
70 (22.3) |
30 (28.6) |
|
Chills |
67 (21.3) |
20 (19.0) |
|
Vomiting |
50 (15.9) |
22 (21.0) |
|
Abdominal pain |
61 (19.4) |
20 (19.0) |
|
Palpitation |
55 (17.5) |
17 (16.2) |
|
Hepatomegaly |
48 (15.3) |
8 (7.6) |
|
Splenomegaly |
40 (12.7) |
12 (11.4) |
|
Fatigue |
34 (10.8) |
8 (7.6) |
|
|
||
|
AL: artemether/lumefantrine; MAS: mefloquine/artesunate |
||
|
Falade and Manyando Malaria Journal 2009 8(Suppl 1):S6 doi:10.1186/1475-2875-8-S1-S6 |
||
